Featured Research

from universities, journals, and other organizations

Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency

Date:
December 29, 1999
Source:
University Of California Los Angeles
Summary:
Based on research conducted at Mattel Children's Hospital at UCLA and other research institutions nationwide, the U.S. Food and Drug Administration (FDA) Thursday approved the first long-acting dosage form of recombinant growth hormone for pediatric growth hormone deficiency (GHD).

New Therapy Significantly Reduces Number of Injections Required

Related Articles


Based on research conducted at Mattel Children's Hospital at UCLA and other research institutions nationwide, the U.S. Food and Drug Administration (FDA) Thursday approved the first long-acting dosage form of recombinant growth hormone for pediatric growth hormone deficiency (GHD).

In clinical trials, Nutropin Depot [somatropin (rDNA origin) for injectable suspension] was shown to significantly increase growth rates in children with GHD. The new formulation requires only one or two doses a month (which may require more than one injection per dose), compared with current growth hormone therapies that require multiple doses per week (oftentimes daily).

"Nutropin Depot, a convenient new treatment option, offers my newly diagnosed patients excellent growth potential with 12 or 24 doses a year, instead of 365," said Dr. Mitchell Geffner, UCLA chief of pediatric endocrinology and a principal investigator of the drug at the Mattel Children's Hospital at UCLA.

Nutropin Depot is a long-acting form of Genentech's recombinant human growth hormone (rhGH) using Alkermes' ProLeaseา injectable extended-release drug delivery system. The new formulation was designed to reduce the frequency of injections by encapsulating the drug in biodegradable microspheres.

In clinical studies, Nutropin Depot was tested for safety, tolerability and efficacy in children with GHD. Ninety-one patients enrolled at 30 sites in the United States were administered the same total dose of Nutropin Depot -- given once monthly or divided into two equal doses given twice monthly.

The most common adverse effects associated with subcutaneous injections of Nutropin Depot were injection-site reactions (53 percent), which occurred in nearly all patients and included redness; post-injection site pain (47%); and nodules (61%). These side effects all resolved without further intervention. Nutropin Depot should not be used in patients with active tumors or acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or to patients having acute respiratory failure.

Growth hormone deficiency, GHD, is a pituitary disorder resulting in short stature and other physical ailments. It affects approximately 20,000 children nationwide. GHD occurs when the production of growth hormone, secreted by the pituitary gland, is disrupted. Since growth hormone plays a critical role in stimulating body growth and development, and is involved in the production of muscle protein and in the breakdown of fats, a decrease in the hormone affects numerous body processes.


Story Source:

The above story is based on materials provided by University Of California Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University Of California Los Angeles. "Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency." ScienceDaily. ScienceDaily, 29 December 1999. <www.sciencedaily.com/releases/1999/12/991229122829.htm>.
University Of California Los Angeles. (1999, December 29). Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/1999/12/991229122829.htm
University Of California Los Angeles. "Research Conducted At Mattel Children's Hospital Leads To New Treatment For Children With Growth Hormone Deficiency." ScienceDaily. www.sciencedaily.com/releases/1999/12/991229122829.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Din้ Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins